US 8481038
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
granted A61KA61K38/179A61K39/3955
Quick answer
US patent 8481038 (Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins) held by Five Prime Therapeutics, Inc. expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Jul 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K38/179, A61K39/3955, A61K45/06, A61P